glp 1 vs glp 2 GLP-1 Receptor Agonists as Treatments for Type Diabetes Comparison of short-acting versus long-acting
Description
doi:10.3390/jcm12010145 Wharton S, Davies M, Dicker D, et al
Participants had not reached a weight plateau, suggesting greater reductions might be observed with longer treatment
Probably not, once you account for what you're actually getting
In a phase 2 trial involving people with obesity, the 12 mg weekly dose of retatrutide resulted in a placebo-adjusted mean weight reduction of 22.1% after 48 weeks of treatment
Balance is everything
For Bicknell, data on the long-term effects will also be valuable
